Riptide Bioscience

Riptide Bioscience, National Cancer Institute partner

Thursday, October 6, 2016

Henry Lopez, executive vice president of Riptide Bioscience, has announced the execution of a Cooperative Research and Development Agreement (NCI CRADA #03045) with the National Cancer Institute (NCI), part of the NIH.  The agreement carries a three-year term and is entitled, Evaluation of Riptide Bioscience’s Proprietary Peptide RP-182 in Preclinical Studies for the Treatment of Pancreatic Cancer.  Research under the CRADA is intended to generate data to support an Investigational New Drug filing of this agent with the FDA.

[Read More]